The Korean Journal of Medicine

  • 제83권3호
  • /
  • Pages.405-410
  • /
  • 2012
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

류마티스관절염 환자에서 Imatinib Mesylate의 치료 효과 보고 1예

Imatinib Mesylate is Effective for Patients Not Only with Chronic Myeloid Leukemia, but Also Rheumatoid Arthritis

  • 정현준 (경희대학교 의과대학 강동경희대학교병원) ;
  • 김대호 (경희대학교 의과대학 강동경희대학교병원) ;
  • 송란 (경희대학교 의과대학 강동경희대학교병원) ;
  • 홍승재 (경희대학교 의과대학 경희의료원 내과) ;
  • 양형인 (경희대학교 의과대학 강동경희대학교병원) ;
  • 어완규 (경희대학교 의과대학 강동경희대학교병원) ;
  • 이상훈 (경희대학교 의과대학 강동경희대학교병원)
  • Jung, Hyun-Jun (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) ;
  • Kim, Dae-Ho (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) ;
  • Song, Ran (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) ;
  • Hong, Seung-Jae (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Medical Center) ;
  • Yang, Hyung-In (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) ;
  • Eo,Wan-Kyu (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong) ;
  • Lee, Sang-Hoon (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong)
  • 발행 : 2012.09.01
⟨ 이전 논문 다음 논문 ⟩

초록

Imatinib mesylate는 만성골수성백혈병 환자에 있어서 타이로신 키나제를 억제하여 그 효과를 나타낸다. 류마티스 관절염에서 활막 조직의 증식과 염증에 타이로신 키나제가 중요한 작용을 한다는 보고가 있어 왔으며 실제로 imatinib mesylate가 류마티스 관절염의 치료에 효과가 있다는 문헌보고가 있어 왔다. 저자들은 만성골수성백혈병을 동반한 류마티스 관절염 환자에서 imatinib mesylate 투여가 효과를 보인 증례를 경험하여 문헌고찰과 함께 보고하는 바이다.

Synovial tissue proliferation and inflammation are regarded as possible causes of rheumatoid arthritis. Activation of tyrosine kinase by numerous cytokines and BCR-ABL translocation contribute to synovial tissue inflammation and the development of rheumatoid arthritis, respectively. Imatinib is a tyrosine kinase-blocking agent that is widely used for treating chronic myeloid leukemia. We found several interesting case reports of patients with refractory rheumatoid arthritis who entered remission after initiating imatinib therapy. However, only one case report on treating rheumatoid arthritis with imatinib was found in Korea. Here, we describe the case of a 50-year-old man who showed clinical remission of rheumatoid arthritis and chronic myeloid leukemia after receiving 3 months of imatinib therapy.

키워드

참고문헌

  1. Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003;22: 329-332. https://doi.org/10.1007/s10067-003-0716-3
  2. Takeuchi T, Abe T. Tyrosine phosphorylated proteins in synovial cells of rheumatoid arthritis. Int Rev Immunol 1998;17:365-381. https://doi.org/10.3109/08830189809054411
  3. Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 2007;217:38-52. https://doi.org/10.1111/j.1600-065X.2007.00504.x
  4. Pereira I, Fialho S, Castro G, Zimmermann A. Imatinib mesylate induces clinical remission in rheumatoid arthritis. Joint Bone Spine 2010;77:372-373. https://doi.org/10.1016/j.jbspin.2010.03.014
  5. Jeon HK, Park YE, Kim SI, et al. Efficacy of imatinib mesylate treatment for a patient with rheumatoid arthritis and who developed chronic myelogenous leukemia. J Rheum Dis 2011;18:118-121. https://doi.org/10.4078/jrd.2011.18.2.118
  6. National Cancer Information Center. Cancer Definition [Internet]. Seoul (KR): National Cancer Information Center, c2012 [cited 2012 Feb 15]. Available from: http://www.cancer.go.kr/ncic/cics_b/ 01/012/1253431_5872.html.
  7. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
  8. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-1420. https://doi.org/10.1136/ard.2004.033241
  9. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502. https://doi.org/10.1002/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J
  10. Senel S, Kaya E, Aydogdu I, Erkurt MA, Kuku I. Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature. Rheumatol Int 2006;26:857-861. https://doi.org/10.1007/s00296-005-0100-5